Literature DB >> 28373634

Risk factors for recurrence of gastric cancer after curative laparoscopic gastrectomy.

Hideya Kashihara1, Mitsuo Shimada, Kozo Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu.   

Abstract

INTRODUCTION: Curative laparoscopic gastrectomy (LG) is associated with good outcomes when performed for early gastric cancers. The aim of this study was to identify risk factors for recurrence after LG.
METHODS: 212 patients with gastric cancer who underwent gastrectomy were enrolled (LG: 143, open gastrectomy, OG: 69). Univariate analysis was used to assess overall (OS) and disease-free survival (DFS) in LG and OG group. Multivariate analysis was used to assess risk factors for recurrence after LG.
RESULTS: In LG, six cases of recurrence were observed (liver: 2, peritoneum: 4). Neither lymph node nor port-site recurrences were evident after LG. The 5-year DFS after LG was 91.4%. Based on univariate analysis of 5-year DFS, three negative prognostic factors-lymph node metastasis, lymphatic invasion, and venous invasion-were identified. The independent risk factor for recurrence of LG was lymph node metastasis. LG and OG showed no significant differences in 5-year DFS among Stage IA, IB, IIA, and IIB groups. Independent risk factors for recurrence after LG or OG were tumor invasion≥muscularis mucosa and lymph node metastasis.
CONCLUSIONS: DFS following LG is comparable to that following OG. Lymph node metastasis is an independent risk factor for gastric cancer recurrence after LG. J. Med. Invest. 64: 79-84, February, 2017.

Entities:  

Mesh:

Year:  2017        PMID: 28373634     DOI: 10.2152/jmi.64.79

Source DB:  PubMed          Journal:  J Med Invest        ISSN: 1343-1420


  7 in total

1.  A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study.

Authors:  Qinghong Guo; Qiang Li; Jiong Wang; Min Liu; Yuping Wang; Zhaofeng Chen; Yuwei Ye; Quanlin Guan; Yongning Zhou
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

2.  Upregulation of Linc-ROR Promotes the Proliferation, Migration, and Invasion of Gastric Cancer Cells Through miR-212-3p/FGF7 Axis.

Authors:  Yanjun Mi; Yongwen Li; Zhuo He; Donghan Chen; Qingqi Hong; Jun You
Journal:  Cancer Manag Res       Date:  2021-02-02       Impact factor: 3.989

3.  Preoperative Low Prealbumin Is Associated With Recurrence in Patients With Stage II/III Gastric Cancer After Laparoscopic D2 Gastrectomy.

Authors:  Chun Gao; Ci Dian Dan Zeng; Yi Xin Tong; Li Zhu; Sheng Zhang
Journal:  Front Surg       Date:  2022-04-01

4.  Preoperative Folate Receptor-Positive Circulating Tumor Cells Are Associated With Occult Peritoneal Metastasis and Early Recurrence in Gastric Cancer Patients: A Prospective Cohort Study.

Authors:  Ci Dian Dan Zeng; Cheng Cheng Jin; Chun Gao; Ai Tang Xiao; Yi Xin Tong; Sheng Zhang
Journal:  Front Oncol       Date:  2022-03-29       Impact factor: 6.244

5.  Meta-Analysis of the Effects of Three-Dimensional Visualized Medical Techniques Hepatectomy for Liver Cancer with and without the Treatment of Sorafenib.

Authors:  Lei Zeng; Yuming Zhu; Peng Guo
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-13       Impact factor: 2.650

6.  Prognostic impact of D2-plus lymphadenectomy and optimal extent of lymphadenectomy in advanced gastric antral carcinoma: Propensity score matching analysis.

Authors:  Weilin Sun; Jingyu Deng; Nannan Zhang; Huifang Liu; Jinyuan Liu; Pengfei Gu; Yingxin Du; Zizhen Wu; Wenting He; Pengliang Wang; Han Liang
Journal:  Chin J Cancer Res       Date:  2020-02       Impact factor: 5.087

7.  The anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation.

Authors:  Peng Lin; Dan-Dan Xiong; Yi-Wu Dang; Hong Yang; Yun He; Dong-Yue Wen; Xin-Gan Qin; Gang Chen
Journal:  Oncotarget       Date:  2017-09-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.